Veracyte, INC 8-K filings

Veracyte, Inc. announced robust second quarter 2026 financial results, exceeding expectations with significant revenue growth, profitability, and the successful launch of two new products.

Veracyte stockholders approved an amendment to the 2023 Equity Incentive Plan, authorizing an additional 3.5 million shares for issuance.

Veracyte, Inc. announced robust first quarter 2026 financial results, with total revenue increasing 21% year-over-year to $139.1 million, driven by strong performance in its Decipher and Afirma tests.

Veracyte, Inc. announced the appointment of Dr. Kevin Haas as its new Chief Development and Technology Officer, effective March 24, 2026.

Veracyte, Inc. announced robust financial results for the fourth quarter and full year ended December 31, 2025, driven by double-digit growth in its core testing business.

Veracyte announced preliminary unaudited financial results for Q4 and full-year 2025, showing significant revenue and testing volume growth, and initiating positive 2026 guidance.

Veracyte, Inc. announced strong third-quarter 2025 financial results, with total revenue increasing 14% and testing revenue up 17% year-over-year, leading to an upward revision of its full-year revenue and profitability guidance.

Veracyte, Inc. announced strong second quarter 2025 financial results, with total revenue increasing 14% year-over-year and raised full-year revenue guidance.

Veracyte, Inc. announced that its stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing the shares reserved for issuance by 2.5 million, alongside the re-election of all director nominees and other key proposals at its 2025 Annual Meeting.

Veracyte's Q1 2025 financial results show an 18% increase in total revenue, driven by strong testing volume growth, particularly in Decipher and Afirma products.

Veracyte announces a 21% increase in fourth-quarter total revenue to $118.6 million and a 23% increase in full-year total revenue to $445.8 million, driven by strong growth in testing revenue.

Veracyte announced a 29% increase in total revenue to $115.9 million and a 151% increase in net income to $15.2 million for the third quarter of 2024, driven by strong growth in its testing business.

Veracyte, Inc. has appointed Tom Miller, Ph.D., and Brent Shafer as new independent directors to its Board, effective immediately.

Veracyte announced a 27% increase in total revenue to $114.4 million and a 118% increase in adjusted EBITDA to $24.0 million for the second quarter of 2024, leading to an increased full-year revenue guidance.

Veracyte's stockholders approved an amendment to the 2023 Equity Incentive Plan, increasing the number of shares available for issuance by 5,000,000.

Veracyte's first quarter 2024 results show a 17% increase in total revenue, driven by a 25% surge in testing revenue.

Veracyte finalizes its acquisition of C2i Genomics and files an amended 8-K report including audited financial statements for C2i and pro forma combined financials.

Veracyte, Inc. has filed a prospectus supplement to register for resale 1,016,965 shares of its common stock issued in connection with the acquisition of C2i Genomics, Inc.

Veracyte, Inc. has filed a prospectus supplement to register for resale 1,681,384 shares of its common stock issued in connection with the acquisition of C2i Genomics, Inc.

Veracyte announced a 22% increase in total revenue for 2023, reaching $361.1 million, and achieved positive cash flow for the second consecutive year.

Veracyte, Inc. announces that board member John L. Bishop will retire at the end of his current term and not seek reelection at the 2024 annual meeting.

Veracyte has finalized its acquisition of C2i Genomics for $70 million, with additional payments possible based on future performance.